Heart failure & cardiomyopathies
Evaluation of the Hemocompatibility of the Direct Oral Anticoagulant Apixaban in Left Ventricular Assist Devices: The DOAC Left Ventricular Assist Device (LVAD) Study
Authors' conclusion
Anticoagulation with apixaban was feasible in patients with an LVAD without an excess of HRAEs or deaths.
Study context
- Population
- Patients with a fully magnetically levitated LVAD
- Participants
- 30 patients
- Comparison
- Apixaban vs warfarin in LVAD recipients
- Apixabann = 16
- Warfarinn = 14reference
- Primary endpoint
- Death or major hemocompatibility-related adverse events (stroke, device thrombosis, major bleeding, aortic root thrombus, arterial non-CNS thromboembolism)
- Follow-up
- 24 weeks
Methodological detailsphase 2, open label, 1:1 randomisation
- Phase 2
- Open label
- 1:1 randomisation
Primary result
As reported in the abstract
Death or major hemocompatibility-related adverse events (HRAEs)
Apixaban
0
events
Warfarin
14%
2 of 14
P = 0.12
Safety
Events
| Outcome | Apixaban | Warfarin |
|---|---|---|
| Major bleeding (gastrointestinal) · 24 weeks | 0 | 2 |
Original publication
Evaluation of the Hemocompatibility of the Direct Oral Anticoagulant Apixaban in Left Ventricular Assist Devices: The DOAC LVAD Study. JACC Heart Fail. Published 7 May 2024. doi:10.
Summarised from the published abstract; every number is checked against it